| Title: |
DOACs vs Warfarin for Post-myocardial Infarction Left Ventricular Thrombus: A GRADE-assessed Meta-Analysis With Trial Sequential Analysis of Randomized Trials. |
| Authors: |
Elbataa, Ahmed; Awashra, Ameer; Elazab, Ahmed; Hammad, Noha; Mansour, Ahmed; Ali, Amro; Elnaggar, Mohamed Yasser; Balbaa, Elsayed; Shubietah, Abdalhakim; Elgendy, Mohamed S.; Elbahloul, Mohammed A.; Zghyer, Fawzi; Al-Sadawi, Mohammed; Salama, Amr |
| Source: |
Clinical & Applied Thrombosis/Hemostasis; 7/13/2026, Vol. 32, p1-17, 17p |
| Subject Terms: |
Warfarin; Myocardial infarction; Safety; Evidence synthesis; Anticoagulants; Randomized controlled trials; Treatment effectiveness; Thrombosis |
| Abstract: |
Background and Purpose: Current AHA and ACC guidelines warrant studies comparing direct oral anticoagulant (DOAC) and warfarin for post-myocardial infarction (MI) left ventricular thrombus (LVT). DOAC is increasingly considered due to its minimal monitoring requirement. However, DOAC efficacy in LVT resolution remains uncertain. We aim to evaluate the efficacy and safety of DOAC versus warfarin in post-MI LVT. Methods: We searched Medline/PubMed, Scopus, Web of Science, and Cochrane. Library databases from inception up to August 2025. The primary outcome was LVT resolution. Secondary outcomes included all-cause death, stroke, and major bleeding rates. Results: Four RCTs encompassing 396 patients (240 DOAC, 156 warfarin) were included. LVT resolution occurred in 90.0% of DOAC patients versus 86.5% in warfarin patients, with no significant difference (RR 0.99, 95% CI 0.94-1.06, p=0.84). Subgroup analysis revealed comparable outcomes for both rivaroxaban and apixaban versus warfarin. Stroke rates were higher in DOAC compared to warfarin but not statically significant between groups (2.5% vs 1.2%, RR 1.37, 95% CI 0.15-12.95). Similarly, all-cause mortality (3.3% vs 1.9%) and major bleeding (1.6% vs 1.9%) showed no significant differences. Conclusion: DOACs demonstrate comparable efficacy and safety to warfarin for post-MI LVT management, with similar rates of thrombus resolution and complications. However, TSA indicates that current evidence is underpowered, and further large-scale randomized trials are required to confirm these findings. [ABSTRACT FROM AUTHOR] |
| : |
Copyright of Clinical & Applied Thrombosis/Hemostasis is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |